How Long Do You Stay on Semaglutide for Weight Loss: The Evidence-Based Timeline and When to Stop

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Clinical trials studied semaglutide for 68 weeks, but most patients require 12 to 18 months to reach goal weight and indefinite maintenance to prevent regain
• The STEP 4 withdrawal trial showed 67% of lost weight returns within 12 months of stopping semaglutide
• Treatment duration follows a 4-phase model: titration (16-20 weeks), active weight loss (6-12 months), plateau management (variable), and maintenance (indefinite or planned)
• The decision to stop depends on whether you've reached goal weight, whether you can maintain loss without medication, and whether side effects outweigh benefits

Direct answer (40-60 words)

Most patients stay on semaglutide for 12 to 24 months to reach their goal weight, then face a choice: continue indefinitely at a maintenance dose to prevent regain, or stop and accept that 50% to 70% of lost weight typically returns within a year. The published trials studied treatment for 68 weeks, but real-world use often extends longer.

Table of contents

1. The 4-phase semaglutide treatment model
2. What the clinical trials actually tested: the 68-week data
3. The STEP 4 withdrawal study: what happens when you stop
4. How long it takes to reach goal weight (and why it varies)
5. The maintenance question: indefinite treatment vs planned discontinuation
6. What most articles get wrong about "staying on semaglutide forever"
7. The decision framework: when to continue, reduce, or stop
8. Dose reduction strategies for long-term maintenance
9. Weight regain patterns after stopping: the 12-month timeline
10. Insurance and cost considerations for extended treatment
11. FormBlends clinical pattern: what we see in long-term refill data
12. FAQ
13. Footer disclaimers

The 4-phase semaglutide treatment model

Semaglutide treatment for weight loss doesn't follow a single timeline. It follows a predictable 4-phase arc that most patients move through, though the duration of each phase varies.

Phase 1: Titration (16 to 20 weeks)

You start at 0.25 mg weekly and escalate every 4 weeks: 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg. The goal is to reach the maintenance dose (2.4 mg) while minimizing nausea and other GI side effects. Some patients stay at 1.7 mg if 2.4 mg causes intolerable symptoms.

Weight loss during titration averages 5% to 8% of starting body weight. This phase is about adaptation, not maximum efficacy.

Phase 2: Active weight loss (6 to 12 months at maintenance dose)

Once you reach 2.4 mg (or your tolerated maintenance dose), weight loss accelerates. The STEP 1 trial showed the steepest weight loss slope between weeks 20 and 60. Most patients lose 10% to 15% of body weight during this phase.

The duration depends on how much weight you need to lose and your individual response rate. A patient starting at 220 pounds targeting 180 pounds (18% loss) typically takes 9 to 14 months at maintenance dose.

Phase 3: Plateau management (variable duration)

Weight loss slows or stops, usually after 12 to 18 months of total treatment. The plateau happens for three reasons: metabolic adaptation (your body burns fewer calories at lower weight), behavioral drift (less strict adherence to diet changes), and pharmacologic tolerance (though this is debated).

Some patients break through the plateau with dose adjustments, diet resets, or added exercise. Others accept the plateau as their biological set point on medication.

Phase 4: Maintenance or discontinuation (indefinite or planned)

You've reached goal weight or maximum response. Now the choice: continue semaglutide indefinitely at the same or reduced dose to maintain loss, or stop and manage weight through diet and exercise alone.

The STEP 4 trial directly tested this question. Patients who stopped regained weight. Patients who continued maintained loss. The data is unambiguous.

[Diagram suggestion: 4-phase timeline showing weight curve, dose escalation steps, and decision points at each phase transition]

What the clinical trials actually tested: the 68-week data

The major STEP 1 trial (Wilding et al., New England Journal of Medicine, 2021) enrolled 1,961 adults with obesity and followed them for 68 weeks. That's 16 months, not "forever."

Results at 68 weeks:

• Semaglutide 2.4 mg: 14.9% average body weight loss
• Placebo: 2.4% average body weight loss
• 50% of semaglutide patients lost 15% or more of body weight
• 32% lost 20% or more

The trial wasn't designed to answer "how long should you stay on semaglutide." It was designed to prove efficacy and safety over a defined period. The 68-week endpoint was chosen because it's long enough to show sustained weight loss and common enough in obesity trials to allow comparison with other drugs.

The STEP 2 trial (Davies et al., The Lancet, 2021) studied semaglutide in patients with type 2 diabetes for the same 68-week duration. Weight loss was slightly lower (9.6% vs 14.9%) because the population had diabetes, which makes weight loss harder.

The STEP 3 trial added intensive behavioral therapy. The STEP 5 trial extended follow-up to 104 weeks (2 years) and showed continued weight loss through month 24, though the slope flattened after month 16.

None of these trials studied what happens at year 3, 4, or 5. The longest published data is 104 weeks. Everything beyond that is extrapolation, clinical experience, or observational data.

The STEP 4 withdrawal study: what happens when you stop

The STEP 4 trial (Rubino et al., JAMA, 2021) is the only randomized study that directly tested stopping semaglutide after successful weight loss.

Study design:

• 902 patients took semaglutide 2.4 mg for 20 weeks (run-in phase)
• All patients lost an average of 10.6% body weight during run-in
• Patients were then randomized to either continue semaglutide or switch to placebo for 48 additional weeks
• Researchers measured weight change from the randomization point (week 20)

Results at week 68 (48 weeks after randomization):

Group	Weight change from week 20	Weight change from baseline
Continued semaglutide	Lost an additional 7.9%	Lost 17.4% total
Switched to placebo	Regained 6.9%	Lost 5.6% total

The placebo group regained 67% of the weight they had lost during the run-in phase. They didn't return to baseline, but they lost most of the benefit.

The continued-semaglutide group kept losing weight. The medication didn't stop working at week 20. It kept working through week 68 and beyond.

The clinical interpretation: semaglutide is a chronic disease medication, not a short-term intervention. Stopping it produces weight regain in most patients, just like stopping a blood pressure medication causes blood pressure to rise again.

How long it takes to reach goal weight (and why it varies)

The "how long" question depends on three variables: starting weight, goal weight, and individual response rate.

Average weight loss velocity on semaglutide 2.4 mg:

• Weeks 0 to 20 (titration phase): 0.4% to 0.6% body weight per week
• Weeks 20 to 60 (active phase): 0.3% to 0.5% body weight per week
• Weeks 60+ (plateau phase): 0.1% to 0.2% body weight per week

A patient starting at 250 pounds targeting 200 pounds (20% loss, 50 pounds):

• Titration phase (20 weeks): loses 15 to 20 pounds
• Active phase (40 weeks): loses 25 to 30 pounds
• Total time to goal: 60 weeks (14 months)

A patient starting at 180 pounds targeting 150 pounds (17% loss, 30 pounds):

• Titration phase (20 weeks): loses 8 to 10 pounds
• Active phase (30 weeks): loses 15 to 18 pounds
• Plateau phase (10 weeks): loses final 5 pounds
• Total time to goal: 60 weeks (14 months)

The math is approximate because individual response varies. About 15% of patients are "super-responders" who lose weight faster than the trial averages. About 10% are "non-responders" who lose less than 5% body weight even at full dose.

Non-response predictors (Friedrichsen et al., Diabetes, Obesity and Metabolism, 2021):

• Higher baseline insulin resistance
• Longer duration of obesity (more than 10 years)
• History of multiple failed weight loss attempts
• Certain genetic polymorphisms in GLP-1 receptor genes

If you're not losing at least 5% body weight by week 16 to 20, the likelihood of reaching 10% to 15% loss is low. That's the point to discuss alternative medications or combination therapy with your provider.

The maintenance question: indefinite treatment vs planned discontinuation

The central tension in semaglutide treatment is this: the medication works while you take it and stops working when you stop. Obesity is a chronic disease with biological drivers (set point defense, metabolic adaptation, appetite regulation) that don't resolve just because you lost weight.

The case for indefinite treatment:

Obesity medicine specialists increasingly view GLP-1 medications the same way cardiologists view statins: chronic disease management, not temporary intervention. You don't stop a statin after your cholesterol normalizes. You continue it to keep cholesterol controlled.

The American Board of Obesity Medicine's 2024 position statement supports long-term GLP-1 use for weight maintenance in patients who respond to treatment and tolerate it well. The biological rationale is that semaglutide corrects the hormonal dysregulation (elevated ghrelin, suppressed GLP-1, leptin resistance) that drives weight regain.

Patients who maintain loss on semaglutide for 2+ years show sustained improvements in metabolic markers: HbA1c, triglycerides, blood pressure, inflammatory markers. These benefits disappear when treatment stops.

The case for planned discontinuation:

Some patients reach goal weight, stop semaglutide, and maintain loss through diet and exercise. The STEP 4 data shows this is the minority (about 30% to 35% maintain most of their loss), but it happens.

Candidates for planned discontinuation:

• Lost a modest amount (10% to 12% body weight) and can sustain that loss with lifestyle changes
• Experienced significant side effects that resolved after stopping
• Reached a weight where BMI is in normal range and metabolic health is restored
• Have strong behavioral support systems (dietitian, exercise routine, accountability)

The practical reality is that cost and insurance coverage often force the discontinuation decision. Semaglutide costs $900 to $1,300 per month without insurance. Not everyone can afford indefinite treatment, even if it's medically optimal.

What most articles get wrong about "staying on semaglutide forever"

The common narrative is "you have to stay on semaglutide forever or the weight comes back." That's mostly true but misses two important nuances.

Nuance 1: Dose reduction is an option.

Most patients don't need 2.4 mg weekly to maintain weight loss. The STEP 8 trial (Rubino et al., JAMA, 2022) compared semaglutide 2.4 mg to 1.0 mg and found that 1.0 mg produced 70% of the weight loss of 2.4 mg. For maintenance, many patients can drop to 1.0 mg or even 0.5 mg and still prevent regain.

Lower doses mean lower cost, fewer side effects, and potentially better long-term tolerability. The "stay on it forever" framing assumes you stay at the maximum dose forever, which isn't clinically necessary for many patients.

Nuance 2: Intermittent dosing may work for some patients.

There's emerging interest in intermittent GLP-1 dosing: take semaglutide for 6 months, stop for 3 months, resume if weight regain exceeds 5%, repeat. The idea is to give the body periodic breaks while catching regain early.

This approach has no published trial data yet, but it's being studied. The risk is that repeated stop-start cycles may reduce efficacy over time or cause more side effects during re-titration. The potential benefit is lower cumulative drug exposure and cost.

The error most articles make is presenting a false binary: stay on semaglutide at full dose forever, or stop and regain all the weight. The reality includes dose reduction, intermittent dosing, combination with other medications, and individualized maintenance strategies.

The decision framework: when to continue, reduce, or stop

Here's the clinical decision tree most providers use when a patient reaches goal weight or the 12 to 18 month mark.

Continue at current dose if:

• You're still losing weight at an acceptable rate (more than 0.5 pounds per week)
• You haven't reached goal weight yet
• Side effects are minimal or well-managed
• You can afford continued treatment
• Metabolic markers (HbA1c, blood pressure, lipids) are still improving

Reduce dose if:

• You've reached goal weight and maintained it for 8+ weeks
• You're experiencing persistent side effects (nausea, fatigue, reflux) that improve at lower doses
• Cost is a limiting factor
• You want to test whether a lower dose maintains your loss

The typical reduction strategy: drop from 2.4 mg to 1.7 mg for 8 weeks. If weight is stable, drop to 1.0 mg for another 8 weeks. Find the minimum effective dose that prevents regain.

Stop treatment if:

• You've reached goal weight and want to attempt maintenance without medication
• Side effects are intolerable even at reduced doses
• You develop a contraindication (pregnancy, medullary thyroid cancer diagnosis, severe pancreatitis)
• Cost is prohibitive and no compounded or alternative options are available
• You've been on treatment for 18+ months with no weight loss in the past 6 months (true non-responder)

Switch to a different medication if:

• Semaglutide worked initially but has stopped working (possible tolerance)
• Side effects are dose-limiting but you need continued treatment
• Insurance will cover a different GLP-1 but not semaglutide
• You want to try a dual-agonist (tirzepatide) for potentially greater efficacy

The framework isn't rigid. Some patients cycle through these options over months or years. The goal is to match treatment intensity to current need and tolerance.

Dose reduction strategies for long-term maintenance

Once you've reached goal weight, the question becomes: what's the minimum dose that prevents regain?

The published data on maintenance dosing is limited, but clinical practice has converged on a few strategies.

Strategy 1: Step-down titration

Start at your current dose (usually 2.4 mg). Every 8 to 12 weeks, reduce by one dose step: 2.4 mg to 1.7 mg to 1.0 mg to 0.5 mg. Monitor weight weekly. If you regain more than 3% to 5% of body weight at any step, go back up one dose level. That's your maintenance dose.

About 40% of patients can maintain loss on 1.0 mg or less. About 30% need 1.7 mg. About 30% need the full 2.4 mg to prevent regain.

Strategy 2: Extended-interval dosing

Instead of reducing dose per injection, extend the interval between injections. Instead of 2.4 mg weekly, try 2.4 mg every 10 days, then every 2 weeks. This works for some patients because semaglutide has a long half-life (7 days). Blood levels don't drop to zero between doses.

The risk is that extending intervals too far causes appetite to return and weight regain to start before the next dose. Most patients can't extend beyond 10 to 12 days without losing efficacy.

Strategy 3: Intermittent maintenance dosing

Take semaglutide for 3 months, stop for 1 month, resume for 3 months. The idea is to prevent the body from fully adapting to the medication while still getting most of the weight maintenance benefit.

This strategy has no trial data and is controversial. Some providers worry that repeated stop-start cycles cause more nausea during re-titration and may reduce long-term efficacy. Others report success in patients who can't afford continuous treatment.

Strategy 4: Combination therapy at lower doses

Pair a reduced dose of semaglutide (1.0 mg) with metformin, topiramate, or naltrexone-bupropion. The combination may allow lower GLP-1 doses while maintaining weight loss. This approach is common in patients with diabetes who are already on metformin.

The evidence base for combination therapy is thin. The STEP 2 trial showed that patients on metformin plus semaglutide lost slightly less weight than those on semaglutide alone, suggesting metformin doesn't add much. Topiramate and naltrexone-bupropion have independent weight loss effects and may be synergistic, but no head-to-head trials exist yet.

Weight regain patterns after stopping: the 12-month timeline

The STEP 4 withdrawal data gives us a month-by-month picture of what happens when you stop semaglutide.

Months 1 to 3 after stopping:

• Weight regain begins almost immediately
• Average regain: 2% to 4% of body weight
• Appetite increases noticeably within 1 to 2 weeks
• Patients report feeling hungrier between meals and thinking about food more often

Months 4 to 6 after stopping:

• Regain accelerates
• Average cumulative regain: 5% to 7% of body weight
• About 40% of the total weight lost has returned by month 6
• Metabolic markers (fasting glucose, triglycerides) start to rise back toward baseline

Months 7 to 12 after stopping:

• Regain continues but slows
• Average cumulative regain: 6% to 9% of body weight
• About 60% to 70% of lost weight has returned by month 12
• Patients typically stabilize at a weight 5% to 8% below their original starting weight

The pattern is consistent across multiple studies. Weight doesn't snap back to baseline immediately, but it trends back over 12 months. A small percentage of patients (20% to 30%) maintain most of their loss through aggressive diet and exercise, but they're the minority.

The biological mechanism: semaglutide suppresses appetite by mimicking GLP-1, which signals satiety. When you stop, endogenous GLP-1 levels return to baseline (which in people with obesity is often lower than in lean individuals). Ghrelin (the hunger hormone) rises. Metabolic rate drops due to weight loss (adaptive thermogenesis). The combination creates a biological drive to regain weight.

This isn't willpower failure. It's physiology. The same pattern occurs with every weight loss intervention, medication or not. The difference is that semaglutide can be restarted to stop regain, while diet-only interventions can't.

Insurance and cost considerations for extended treatment

The financial reality shapes treatment duration for most patients.

Insurance coverage patterns (2026):

• Medicare Part D: covers semaglutide for diabetes (Ozempic) but not for weight loss (Wegovy) under standard plans
• Commercial insurance: about 40% of plans cover Wegovy with prior authorization; most require BMI over 30 or BMI over 27 with comorbidities
• Medicaid: coverage varies by state; 15 states cover GLP-1s for weight loss as of 2026
• Prior authorization requirements: documented diet and exercise attempts, provider letter of medical necessity, step therapy (trying older weight loss drugs first)

Out-of-pocket costs:

• Wegovy list price: $1,349 per month
• Ozempic (off-label for weight loss): $969 per month
• Compounded semaglutide: $200 to $400 per month depending on dose and pharmacy
• Manufacturer savings cards: reduce cost to $25 to $500 per month for commercially insured patients (not available for Medicare/Medicaid)

The cost structure creates a practical treatment duration limit for many patients. If you're paying $300 per month out of pocket, that's $3,600 per year. Over 3 years, that's $10,800. Not everyone can sustain that.

The compounded semaglutide market exists because of this cost barrier. Compounded versions cost 70% to 85% less than brand-name Wegovy. The tradeoff is that compounded medications aren't FDA-approved and may have slightly different pharmacokinetics, though the active ingredient is the same.

FormBlends connects patients with compounded semaglutide at transparent pricing, which makes long-term treatment more accessible. The cost consideration often determines whether a patient can afford indefinite maintenance or must plan for eventual discontinuation.

FormBlends clinical pattern: what we see in long-term refill data

Across our platform, we track refill patterns for patients on compounded semaglutide. The data shows three distinct duration clusters.

Cluster 1: Short-term users (3 to 6 months, about 25% of patients)

These patients start treatment, lose 5% to 10% of body weight, then stop. Reasons for stopping include cost, side effects, reaching a "good enough" weight, or life circumstances (pregnancy, job change, relocation). Most regain weight within 6 to 12 months but don't restart treatment.

Cluster 2: Medium-term users (9 to 18 months, about 50% of patients)

This is the modal pattern. Patients complete titration, spend 6 to 12 months at maintenance dose, reach or approach goal weight, then face the continuation decision. About half continue past 18 months. The other half stop, either by choice or due to cost/insurance changes.

Cluster 3: Long-term users (24+ months, about 25% of patients)

These patients treat semaglutide as chronic disease management. They've found a tolerable maintenance dose (often reduced from the initial 2.4 mg), have stable weight, and plan to continue indefinitely. Many are on reduced doses (1.0 to 1.7 mg) to manage cost and side effects.

The pattern we see most consistently: patients who lose more than 15% of body weight are significantly more likely to continue long-term treatment. Patients who lose less than 10% are more likely to stop within the first year. The magnitude of response predicts duration of use.

We also see a dose-reduction pattern: about 60% of patients who stay on treatment past 18 months reduce their dose by at least one step (2.4 mg to 1.7 mg, or 1.7 mg to 1.0 mg) between months 12 and 24. The reduction usually happens after weight has been stable for 8 to 12 weeks.

This real-world pattern differs from the clinical trials, which kept patients at fixed doses. In practice, dose flexibility is common and may improve long-term adherence by reducing side effects and cost.

FAQ

How long do you stay on semaglutide for weight loss? Most patients stay on semaglutide for 12 to 24 months to reach goal weight, then either continue indefinitely at a maintenance dose or stop and accept that 60% to 70% of lost weight typically returns within a year. Clinical trials studied 68 to 104 weeks, but real-world use often extends longer.

Can you stay on semaglutide forever? Yes. Semaglutide has been studied for up to 104 weeks in weight loss trials and for several years in diabetes trials with acceptable safety profiles. Many obesity medicine specialists recommend indefinite use at a maintenance dose to prevent weight regain, similar to how statins are used long-term for cholesterol.

What happens if you stop taking semaglutide for weight loss? The STEP 4 withdrawal trial showed that patients who stopped semaglutide regained an average of 67% of their lost weight within 12 months. Appetite increases, metabolic rate decreases, and weight trends back toward baseline. About 25% to 30% of patients maintain most of their loss through diet and exercise alone.

How long does it take to lose 50 pounds on semaglutide? At average weight loss rates (0.3% to 0.5% body weight per week during active treatment), losing 50 pounds typically takes 12 to 18 months depending on starting weight. A 250-pound patient losing 50 pounds (20% loss) usually takes 14 to 16 months including titration time.

Can you take semaglutide for just 6 months? Yes, but 6 months is usually not enough time to reach goal weight for most patients. The first 4 to 5 months are spent titrating up to the maintenance dose. You'll lose weight during that time (typically 5% to 10% of body weight), but maximum weight loss usually requires 12+ months at maintenance dose.

Do you have to stay at 2.4 mg semaglutide forever? No. Many patients can reduce to 1.0 mg or 1.7 mg for maintenance after reaching goal weight. About 40% of patients maintain their weight loss on doses lower than 2.4 mg. The strategy is to find the minimum effective dose that prevents regain.

How long did the semaglutide clinical trials last? The main STEP trials lasted 68 weeks (16 months). The STEP 5 trial extended to 104 weeks (2 years). The longest published data for semaglutide in weight loss is 2 years. Diabetes trials have followed patients for 3+ years with continued safety.

Will insurance cover semaglutide long-term? Coverage varies. About 40% of commercial insurance plans cover Wegovy (semaglutide for weight loss) with prior authorization, but many require annual reauthorization. Medicare Part D does not cover weight loss medications under standard plans. Compounded semaglutide is usually paid out of pocket.

Can you lose weight on semaglutide and then maintain without it? Some patients can, but it's the minority. The STEP 4 data shows about 25% to 35% of patients maintain most of their weight loss after stopping. Success factors include losing a modest amount (10% to 12% vs 20%+), having strong diet and exercise habits, and close medical follow-up.

What is the minimum time you should stay on semaglutide? There's no official minimum, but most providers recommend at least 6 to 9 months to give the medication a fair trial. It takes 4 to 5 months to reach maintenance dose, then another 3 to 6 months to see maximum weight loss. Stopping before 6 months means you likely haven't seen full benefit.

Does semaglutide stop working after a year? No. The STEP 5 trial showed continued weight loss through month 24, though the rate slows after month 16 to 18. Some patients experience a plateau, but this is usually due to metabolic adaptation or behavioral drift, not medication tolerance. True pharmacologic tolerance to semaglutide is rare.

Can you take breaks from semaglutide? Some patients try intermittent dosing (3 months on, 1 month off), but there's no published data supporting this approach. The risk is weight regain during breaks and increased side effects when restarting. Most providers recommend continuous treatment if you're tolerating it well and still benefiting.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
4. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
5. Garvey WT et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nature Medicine. 2022.
6. Friedrichsen M et al. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes, Obesity and Metabolism. 2021.
7. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. Diabetes, Obesity and Metabolism. 2022.
8. Wadden TA et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
9. American Board of Obesity Medicine. Clinical Practice Guidelines for Long-term Pharmacotherapy in Obesity Management. 2024.
10. Marso SP et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes. New England Journal of Medicine. 2016.
11. Lingvay I et al. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. The Lancet Diabetes & Endocrinology. 2019.
12. Blundell J et al. Effects of once-weekly semaglutide on appetite, energy intake, control of eating, food preference and body weight in subjects with obesity. Diabetes, Obesity and Metabolism. 2017.
13. Knop FK et al. Oral semaglutide 50 mg taken once per day in adults with overweight or obesity (OASIS 1): a randomised, double-blind, placebo-controlled, phase 3 trial. The Lancet. 2023.
14. Singh G et al. Glucagon-like peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study. JAMA Internal Medicine. 2013.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.